论文部分内容阅读
目的:观察稳心颗粒与厄贝沙坦治疗糖尿病合并阵发性房颤的疗效。方法:选择糖尿病合并阵发性房颤病人90例,随机分为厄贝沙坦组、稳心颗粒组、稳心颗粒加厄贝沙坦组(联合组)3组。疗程均为6个月,观察3组病人用药前后阵发性房颤控制率、主要症状改善率及安全性。结果:稳心颗粒组房颤控制率为80.0%,临床疗效为96.7%;厄贝沙坦组房颤控制率为76.7%,临床疗效为93.3%;联合组总房颤控制率为96.7%,临床疗效为96.7%。在阵发性房颤控制率方面,联合组分别与稳心颗粒组、厄贝沙坦单独组比较有统计学意义(P<0.05)。结论:稳心颗粒与厄贝沙坦联合用药控制糖尿病合并阵发性房颤中效果显著,在治疗中未发现明显的负性心率。
Objective: To observe the effect of Wenxinkeli and irbesartan on diabetic patients with paroxysmal atrial fibrillation. Methods: 90 patients with diabetes mellitus complicated with paroxysmal atrial fibrillation were randomly divided into 3 groups: irbesartan group, Wenxin Granule group and Wenxin Granule plus Irbesartan group (combined group). The course of treatment was 6 months. The control rate of paroxysmal atrial fibrillation, improvement of main symptoms and safety before and after treatment were observed in 3 groups of patients. Results: The control rate of atrial fibrillation in Wenxin Granule group was 80.0%, the clinical effect was 96.7%; the control rate of atrial fibrillation in irbesartan group was 76.7%, the clinical efficacy was 93.3%; the control rate of total atrial fibrillation in combination group was 96.7% Clinical efficacy was 96.7%. In the control rate of paroxysmal atrial fibrillation, the combination group and Wenxin Granule group, irbesartan alone group was statistically significant (P <0.05). Conclusion: The combination of Wenxinkelian and irbesartan in the treatment of diabetes mellitus complicated with paroxysmal atrial fibrillation has a significant effect. No significant negative heart rate was found in the treatment.